Brümmendorf, Tim H. http://orcid.org/0000-0002-9677-3723
Cortes, Jorge E. http://orcid.org/0000-0002-8636-1071
Milojkovic, Dragana
Gambacorti-Passerini, Carlo http://orcid.org/0000-0001-6058-515X
Clark, Richard E.
le Coutre, Philipp
Garcia-Gutierrez, Valentin http://orcid.org/0000-0003-4752-0815
Chuah, Charles
Kota, Vamsi http://orcid.org/0000-0002-5290-9289
Lipton, Jeffrey H.
Rousselot, Philippe http://orcid.org/0000-0003-3238-4494
Mauro, Michael J. http://orcid.org/0000-0002-2251-4032
Hochhaus, Andreas
Hurtado Monroy, Rafael
Leip, Eric
Purcell, Simon
Yver, Anne
Viqueira, Andrea
Deininger, Michael W.
,
Funding for this research was provided by:
Pfizer
Article History
Received: 12 January 2022
Accepted: 28 April 2022
First Online: 28 May 2022
Competing interests
: THB served as a consultant for Janssen, Merck, Novartis, and Pfizer; received research funding from Novartis and Pfizer; received honorarium from Pfizer. JEC served as a consultant for Amphivena Therapeutics, Astellas Pharma, Bio-Path Holdings Inc, BiolineRx, Bristol Myers Squibb, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, Pfizer, and Takeda; received research funding from Astellas Pharma, Bristol Myers Squibb, Daiichi Sankyo, Immunogen, Jazz Pharmaceuticals, Merus, Novartis, Pfizer, Sun Pharma, Takeda, Tolero Pharmaceuticals, and Tovagene. DM served as a consultant for Bristol Myers Squibb, Incyte, Pfizer, and Novartis; received research funding from Pfizer. CG-P served as a consultant for Bristol Myers Squibb; received research funding and honorarium from Pfizer. REC served as a consultant for AbbVie, Bristol Myers Squibb, Jazz Pharmaceuticals, and Novartis; received research funding from Bristol Myers Squibb, Novartis, and Pfizer; received honorarium from Ariad/Incyte, Bristol Myers Squibb, Novartis, and Pfizer. PleC received honorarium from Incyte, Novartis, and Pfizer; received research funding from Pfizer. VG-G served as a consultant for Bristol Myers Squibb, Incyte, Novartis, and Pfizer; received research funding from Pfizer. CC received research funding from Bristol Myers Squibb and Pfizer; received honorarium from Bristol Myers Squibb, Korea Otsuka Pharmaceuticals, and Novartis. VK received honorarium from Ariad, Incyte, Novartis, Pfizer, and Xcenda; received research funding from Pfizer. JHL served as a consultant for Bristol Myers Squibb, Novartis, Pfizer, and Takeda; received research funding from Bristol Myers Squibb, Novartis, Pfizer, and Takeda; received honorarium from Bristol Myers Squibb, Pfizer, and Takeda. PR served as a consultant for Bristol Myers Squibb, Incyte, Novartis, Pfizer, and Takeda; received research funding from Pfizer. MJM served as a consultant for Bristol Myers Squibb, Novartis, Takeda, and Pfizer; received research funding from Bristol Myers Squibb, Novartis, Pfizer, and Sun Pharma/SPARC. AH received research funding from Bristol Myers Squibb, Incyte, Novartis, and Pfizer; received honoraria from Bristol Myers Squibb, Incyte, Novartis, and Pfizer. RHM served as a consultant for Incyte and Pfizer; received research funding from Pfizer. EL, SP, AY, and AV are employees of Pfizer and own stocks in Pfizer. MWD served as a consultant for Ariad, Blueprint Medicine, Bristol Myers Squibb, Galena Biopharma, Incyte, Novartis, and Pfizer; received research funding from Bristol Myers Squibb, Celgene, Gilead Sciences, Incyte, Novartis, and Pfizer; received honorarium from Ariad, Blueprint Medicine, Bristol Myers Squibb, Galena Biopharma, Incyte, Novartis, and Pfizer.